news-med.jpg

Evotec Achieves First Milestone In Neurodegeneration Alliance With Celgene

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its strategic alliance with Celgene has reached a first milestone triggering revenues of $ 5.0 m to Evotec, which are recognised in the third quarter of 2017. The milestone is due to the successful completion ...

Topics: Corporate, Drug Development, Drug Discovery, Partner Research Organization Read More

Evotec and MaRS Innovation Establish Academic Bridge “LAB150” in Toronto

We are pleased to share the press release about the launch of “LAB150” announced by Evotec and MaRS Innovation.

Topics: Corporate, Drug Development, Drug Discovery, Partner Research Organization Read More

Evotec to Acquire Aptuit, Expanding Leadership in External Innovation

We are pleased to share the press release published today about the agreement between Evotec AG and Aptuit under which Evotec will acquire Aptuit.

Topics: Corporate, Acquisition, Drug Development, Drug Discovery, Contract Reseach Organization, Partner Research Organization, Integrated CMC, IND Enabling Read More

Read our article on Form Selection Problems in the Pharmaceutical Field

Our Material Sciences and API experts Matteo Daldosso, Zadeo Cimarosti and Brigida Allieri have recently published an article where they discuss about the "form selection problem in the pharmaceutical field" and the importance of X-Rays Powder Diffraction technique to respond to the implications ...

Topics: Drug Development, Active Pharmaceutical Ingredient, CMC, Partner Research Organization, Integrated CMC, Form selection, Material Sciences Read More

Aptuit Announces Strategic Provider Agreement with Regulus Therapeutics

Provides range of discovery, CMC and non-clinical services Greenwich, CT, June 8, 2017 - Dr. Jonathan Goldman, CEO, Aptuit LLC, announced a strategic provider relationship between Aptuit, a leading Partnership Research Organization, and Regulus Therapeutics Inc (Nasdaq:RGLS), an innovative ...

Topics: Drug design and discovery, Drug Development, Partner Research Organization, microRNA Read More

Aptuit's Collaboration with MGH Covered on OneNucleus Spring 2017 Newsletter

Our recent collaboration with Massachusetts General Hospital (MGH) on the identification and validation of novel targets in Gram-negative bacteria is covered in the Spring edition of OneNucleus Newsletter. Read the full article on page 8 with our expert, Antonio Felici.

Topics: Drug design and discovery, Antibiotic Resistance, Gram-negative bacteria, Partner Research Organization, Antibacterial Read More

Aptuit Announces Alignment of Organizational Structure to Integrated Solution Delivery: Henning Steinhagen Appointed as President, Research and Development Operations

Greenwich, CT, April 6, 2017 – Jonathan Goldman, CEO of Aptuit LLC, announced today that Henning Steinhagen, PhD, has been named as President, Research and Development Operations. Henning will continue in his existing role of Site-Head at Aptuit, Verona, Italy whilst assuming oversight of Aptuit ...

Topics: Corporate, Partner Research Organization Read More

Bioversys AG and Aptuit Announce Collaboration to Identify Novel Approaches to Treat Serious Infections from Gram-negative Pathogens

Basel, Switzerland and Greenwich, CT – March 7, 2017 - Bioversys AG and Aptuit today announced the start of a joint collaboration aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria. Aptuit and BioVersys hope that innovative approaches can address ...

Topics: Drug design and discovery, Antibiotic Resistance, Drug Discovery, Gram-negative bacteria, Partner Research Organization Read More